Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era

Damast, Shari; Ho, Alice Y.; Montgomery, Leslie L.; Fornier, Monica; Ishill, Nicole; Elkin, Elena B.; Beal, Kathryn; McCormick, Beryl

doi:10.1016/j.ijrobp.2009.06.042

Cited by 51 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparing the taxane non-containing protocols to concomitant TE protocol in our study response rates and survival data were equivalent and analogous with results of these and other [36,37] groups. We could also confirm, that achieving pCR renders a greater probability of longer PFS and LPFS, but not significant tendency in OS data.…”

Section: Discussionsupporting

confidence: 84%

Inflammatory Breast Cancer—Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response

Horváth

Torday

Hitre

et al. 2010

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Our retrospective analysis compared the effectiveness of conventional antracycline-containing protocols (A+) and docetaxel/epirubicine (TE) as primary systemic chemotherapies (PSCT) for inflammatory breast cancer (IBC). Seventy IBC patients received either A + (n = 48) or TE (n = 22) as PSCT. The objective clinical response and clinical benefit rate of treated patients were 54.3% (A+: 54,2% vs. TE: 54,5%; p = 0,28) and 92.8% (A+: 91,7% vs. TE: 95,5%; p = 0,57), respectively. The clinical complete response rate (cCR) was 23.2% (A+: 27,1% vs. TE:4,5%; χ (2) = 4,79; p = 0,03) with 7.14% (A+: 10,4% vs. TE:0%; χ (2) = 2,47; p = 0,12) of pathological complete responses (pCR). The median progression free (PFS)/local progression free (LPFS)/overall survival (OS) was 2.0/5.4/4.0 years, respectively. Patients achieving cCR had a tendency for better survival parameters than patients with less than cCR. Response rates or survival data were not statistically different in the two chemotherapy (CT) treatment groups. The survival was not influenced by the number of CT cycles in either protocols. In this set of patients, the clinical efficacy of the two alternative primary systemic chemotherapies (A + and TE) is equivalent in the treatment of inflammatory breast cancer (IBC), despite of the significant difference in favour of A + noticed in CRs. Six cycles of CT could be enough for patients achieving CR, however sequential pre- and/or postoperative CT with non cross-resistant drugs should be considered for non-responders.

show abstract

Section: Discussionsupporting

confidence: 84%

Inflammatory Breast Cancer—Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response

Horváth

Torday

Hitre

et al. 2010

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Recent research has focused on IBC-specific approaches using hyperfractionated radiotherapy or daily bolus application to increase skin dose to improve locoregional control rates among women with IBC. [19][20][21][22] Although data indicate that postmastectomy accelerated hyperfractionated radiation to 66 grays with radiation delivered to chest wall as well as the axillary, infraclavicular, supraclavicular, and internal mammary lymph node regions improves locoregional, distant metastases-free, and overall survival among women with IBC, this is not standard practice in the community. Similarly, once-daily regimens with tailored daily bolus regimens to increase dose intensity in the skin for women with IBC has been reported to yield excellent locoregional control but is not standard practice in the community.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, once-daily regimens with tailored daily bolus regimens to increase dose intensity in the skin for women with IBC has been reported to yield excellent locoregional control but is not standard practice in the community. 22 It is therefore likely that delivered adjuvant radiotherapy to women with IBC coded within SEER is not homogenous and may thus contribute to the survival differences observed.…”

Section: Discussionmentioning

confidence: 99%

Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early

Dawood

Ueno

Valero

et al. 2010

Cancer

126

View full text Add to dashboard Cite

BACKGROUND: Significant improvements in the survival of women with breast cancer have been observed and are attributed to a multidisciplinary approach and the introduction of polychemotherapy and endocrine regimens. The objective of this population-based study was to determine whether women with inflammatory breast cancer (IBC) who received treatment in a modern era had a poorer survival compared those with non-IBC locally advanced breast cancer (LABC). METHODS: The Surveillance, Epidemiology, and End Results program registry was searched to identify women with stage IIIB/C breast cancer diagnosed between 2004 and 2007 who had undergone surgery and radiotherapy. Patients were categorized as either having IBC or non-IBC LABC according the sixth edition of the American Joint Committee on Cancer (AJCC) criteria. Breast cancer-specific survival (BCS) was estimated using the Kaplan-Meier product limit method and compared across groups using the log-rank statistic. Cox models were then fitted to compare the association between breast cancer type and BCS after adjusting for patient and tumor characteristics. RESULTS: A total of 828 (19.2%) women and 3476 (80.8%) women had stage IIIB/C IBC and non-IBC LABC, respectively. The median follow-up was 19 months. The 2-year BCS rate was 90% (95% confidence interval [95% CI], 88%-91%) for the entire cohort and 84% (95%CI, 80%-87%) and 91% (95%CI, 90%-91%) among women with IBC and non-IBC LABC, respectively. In the multivariable model, patients with IBC were found to have a 43% increased risk of death from breast cancer compared with patients with non-IBC LABC (hazard ratio, 1.43; 95%CI, 1.10-1.86 [P ¼ .008]). CONCLUSIONS: In the era of multidisciplinary management and anthracycline-based and taxane-based polychemotherapy regimens, women with IBC continue to have worse survival outcomes compared with those with non-IBC LABC.

show abstract

“…3,10-14 Five-year OS rates for patients with IBC presenting without metastatic disease range from 40-61 %, compared with 41-86 % in LABC. 10,[13][14][15][16][17][18][19][20][21] The current standard of care for newly diagnosed, nonmetastatic IBC includes preoperative chemotherapy,…”

mentioning

confidence: 99%

Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management

et al. 2015

View full text Add to dashboard Cite

show abstract

Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era

Abstract: Excellent locoregional control was observed in this population of IBC patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy. Distant metastases-free survival remains a significant therapeutic challenge.

Cited by 51 publications

References 30 publications

Inflammatory Breast Cancer—Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response

Inflammatory Breast Cancer—Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response

Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early

Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management

Contact Info

Product

Resources

About